BTIG Reiterates Buy on Stoke Therapeutics, Maintains $39 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.6%

Neg 0% Neu 90.6% Pos 0%

BTIG analyst Thomas Shrader reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $39 price target.

Comments

No comments yet. Be the first!